Johan Wedell-Wedellsborg Sells 17,243 Shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Director Johan Wedell-Wedellsborg sold 17,243 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $27.00, for a total value of $465,561.00.

Johan Wedell-Wedellsborg also recently made the following trade(s):

  • On Wednesday, August 28th, Johan Wedell-Wedellsborg sold 49,357 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $27.08, for a total transaction of $1,336,587.56.
  • On Friday, August 30th, Johan Wedell-Wedellsborg sold 89,166 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $26.58, for a total transaction of $2,370,032.28.
  • On Wednesday, August 21st, Johan Wedell-Wedellsborg sold 168,244 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $27.57, for a total transaction of $4,638,487.08.

YMAB stock opened at $30.15 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.04 and a quick ratio of 9.04. The company has a 50 day moving average price of $25.38 and a 200 day moving average price of $23.46. Y-mAbs Therapeutics, Inc has a fifty-two week low of $15.17 and a fifty-two week high of $31.00. The stock has a market capitalization of $992.31 million and a PE ratio of -20.10.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Wednesday, August 14th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.05). As a group, equities analysts expect that Y-mAbs Therapeutics, Inc will post -2.1 earnings per share for the current fiscal year.

A number of research firms have recently issued reports on YMAB. Wedbush began coverage on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $38.00 target price for the company. Zacks Investment Research cut shares of Y-mAbs Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 22nd. Cowen reiterated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Monday, July 1st. Finally, HC Wainwright set a $40.00 target price on shares of Y-mAbs Therapeutics and gave the company a “buy” rating in a research note on Monday, August 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $32.50.

Several institutional investors have recently modified their holdings of the business. Nuveen Asset Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the 2nd quarter valued at $1,827,000. Price T Rowe Associates Inc. MD raised its position in shares of Y-mAbs Therapeutics by 16.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 748,351 shares of the company’s stock valued at $17,115,000 after acquiring an additional 108,054 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Y-mAbs Therapeutics during the 2nd quarter valued at $686,000. Cormorant Asset Management LP raised its position in shares of Y-mAbs Therapeutics by 39.8% during the 2nd quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock valued at $22,870,000 after acquiring an additional 284,518 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Y-mAbs Therapeutics by 72.0% during the 2nd quarter. Vanguard Group Inc. now owns 489,582 shares of the company’s stock valued at $11,196,000 after acquiring an additional 205,021 shares during the last quarter. Institutional investors own 32.06% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: Elliott Wave Theory

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.